不同剂型亮丙瑞林治疗女童中枢性性早熟的临床疗效比较<sup>*</sup>

doi:10.3969/j.issn.1671-7171.2024.10.005

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1253 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】比较亮丙瑞林3M剂型与1M剂型治疗女童中枢性性早熟(CPP)的临床疗效。【方法】回顾性分析2022年7月至2023年8月本院儿童保健科收治的35例CPP患儿,根据治疗方法的不同将其分为观察组(n=17)和对照组(n=18)。比较两组患者治疗前后性激素水平[黄体生成素(LH)、卵泡刺激素(FSH)、雌二醇(E₂)]、子宫长度、卵巢容积、身高、体重、骨龄/实际年龄,比较两组不良反应发生情况。【结果】两组治疗前后子宫长度、左侧卵巢容积、右侧卵巢容积、骨龄/实际年龄、身高、体重指数(BMI)比较,差异均无统计学意义(P>0.05)。治疗3个月,两组LH、FSH峰值水平均低于治疗前,差异有统计学意义(P<0.05);治疗3个月和6个月,两组患儿血清LH、FSH、E₂水平低于治疗前,差异有统计学意义(P<0.05);治疗3个月,观察组血清LH、FSH水平高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。【结论】亮丙瑞林两种剂型治疗CPP女童的临床疗效及安全性相当,但长效剂型具有经济性及便捷性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周源源
	赵莎

关键词 ：青春期,早熟/药物疗法, 亮丙瑞林/投药和剂量, 儿童, 治疗结果

Abstract：【Objective】To compare the clinical efficacy of dosage form 3M and 1M of leuprorelin in the treatment of central precocious puberty (CPP) in girls. 【Methods】A total of 35 children with CPP admitted to the Department of Child Health Care of our hospital from July 2022 to August 2023 were retrospectively analyzed and divided into the observation group (n=17) and the control group (n=18) according to different treatment methods. Sex hormone levels [luteinizing hormone (LH), follicle stimulating hormone (FSH), estradiol (E₂)], uterine length, ovarian volume, height, weight, bone age/chronological age of the two groups before and after treatment were compared, and the occurrence of adverse reactions between the two groups were compared. 【Results】There were no significant differences in uterine length, left ovarian volume, right ovarian volume, bone age/actual age, height and body weight index (BMI) between the two groups before and after treatment (P>0.05). After 3 months of treatment, the peak levels of LH and FSH in 2 groups were lower than before treatment, and the difference was statistically significant (P<0.05). After 3 and 6 months of treatment, the levels of serum LH, FSH and E₂ in the two groups were lower than before treatment, and the differences were statistically significant (P<0.05). After 3 months of treatment, serum LH and FSH levels in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The two formulations of leuprorelin have similar clinical efficacy and safety in the treatment of CPP girls, and the long-acting formulations are economical and convenient.

Key words： Puberty, Precocious/DT Leuprolide/AD Child Treatment Outcome

收稿日期: 2024-08-04

中图分类号:

R725.85

基金资助:^*长沙市科技计划项目(kq2208089)

引用本文:

周源源, 赵莎. 不同剂型亮丙瑞林治疗女童中枢性性早熟的临床疗效比较^*[J]. 医学临床研究, 2024, 41(10): 1472-1474.
ZHOU Yuanyuan, ZHAO Sha. Comparison of Clinical Efficacy of Different Formulations of Leuprorelin in the Treatment of Central Precocious Puberty in Girls. JOURNAL OF CLINICAL RESEARCH, 2024, 41(10): 1472-1474.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.10.005 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I10/1472